| Literature DB >> 28099887 |
Michael Karbiener1, Barbara Darnhofer2, Marie-Therese Frisch3, Beate Rinner3, Ruth Birner-Gruenberger2, Markus Gugatschka4.
Abstract
Injuries of the vocal folds frequently heal with scar formation, which can have lifelong detrimental impact on voice quality. Current treatments to prevent or resolve scars of the vocal fold mucosa are highly unsatisfactory. In contrast, the adjacent oral mucosa is mostly resistant to scarring. These differences in healing tendency might relate to distinct properties of the fibroblasts populating oral and vocal fold mucosae. We thus established the in vitro cultivation of paired, near-primary vocal fold fibroblasts (VFF) and oral mucosa fibroblasts (OMF) to perform a basic cellular characterization and comparative cellular proteomics. VFF were significantly larger than OMF, proliferated more slowly, and exhibited a sustained TGF-β1-induced elevation of pro-fibrotic interleukin 6. Cluster analysis of the proteomic data revealed distinct protein repertoires specific for VFF and OMF. Further, VFF displayed a broader protein spectrum, particularly a more sophisticated array of factors constituting and modifying the extracellular matrix. Conversely, subsets of OMF-enriched proteins were linked to cellular proliferation, nuclear events, and protection against oxidative stress. Altogether, this study supports the notion that fibroblasts sensitively adapt to the functional peculiarities of their respective anatomical location and presents several molecular targets for further investigation in the context of vocal fold wound healing. BIOLOGICAL SIGNIFICANCE: Mammalian vocal folds are a unique but delicate tissue. A considerable fraction of people is affected by voice problems, yet many of the underlying vocal fold pathologies are sparsely understood at the molecular level. One such pathology is vocal fold scarring - the tendency of vocal fold injuries to heal with scar formation -, which represents a clinical problem with highly suboptimal treatment modalities. This study employed proteomics to obtain comprehensive insight into the protein repertoire of vocal fold fibroblasts, which are the cells that predominantly synthesize the extracellular matrix in both physiological and pathophysiological conditions. Protein profiles were compared to paired fibroblasts from the oral mucosa, a neighboring tissue that is remarkably resistant to scarring. Bioinformatic analyses of the data revealed a number of pathways as well as single proteins (e.g. ECM-remodeling factors, transcription factors, enzymes) that were significantly different between the two fibroblast types. Thereby, this study has revealed novel interesting molecular targets which can be analyzed in the future for their impact on vocal fold wound healing.Entities:
Keywords: Fibroblasts; Fibrosis; Laryngology; Oral mucosa; Vocal folds; Wound healing
Mesh:
Substances:
Year: 2017 PMID: 28099887 PMCID: PMC5389448 DOI: 10.1016/j.jprot.2017.01.010
Source DB: PubMed Journal: J Proteomics ISSN: 1874-3919 Impact factor: 4.044
Fig. 1Comparative cellular characteristics of paired vocal fold fibroblasts (VFF) and oral mucosa fibroblasts (OMF). (A) Representative phase contrast microscopy images from two biological replicates (BR1, BR2); scale bar: 100 μm. (B) Mean cell diameter ± s.e.m. (n = 4) was obtained from trypsinized (i.e. spherical) cells. Data was analyzed by paired t-test; *… P ≤ 0.05. (C) Growth curves of fibroblast pairs. (D) Phase contrast microscopy images of 3D spheroid cultures (BR2) were acquired 6 h and 24 h post re-plating; scale bar: 100 μm.
Fig. 2Cellular response to pro-fibrotic stimulus. Paired vocal fold fibroblasts (VFF) and oral mucosa fibroblasts (OMF; n = 4) were exposed to TGF-β1 (5 ng/mL) or vehicle (“C”) and expression of (A) α-smooth muscle actin (ACTA2) and (B) interleukin 6 (IL6) was analyzed 24 h and 72 h later. TGF-β1 effects were analyzed by paired t-test.
Fig. 3Proteomic profiling of paired vocal fold fibroblasts (VFF) and oral mucosa fibroblasts (OMF). (A) Venn diagram depicting the number of proteins detected solely in VFF, solely in OMF, and in both cell types. (B) Number of robustly detected proteins (≥2 peptide counts (razor + unique)) for each biological replicate (BR1–BR4). (C) Heat map showing log10-transformed normalized LFQ intensity values for three groups: group 1, 520 proteins detected in both cell types; group 2, 45 proteins detected only in VFF, group 3, 9 proteins detected only in OMF. Within each group, proteins are sorted in a decreasing manner according to their mean abundance. Clustering tree resulting from unsupervised clustering of samples is shown on top.
Fig. 4Cell type-selective protein sets and their significantly enriched Gene Ontology terms. Groups of proteins detected solely in (A) vocal fold fibroblasts (VFF) or (B) oral mucosa fibroblasts (OMF) are depicted as heat map with proteins specified by gene symbol. Right part of panels depicts results of statistical overrepresentation tests performed for the three main Gene Ontology (GO) aspects molecular function, cellular component, and biological process. Grey fields indicate significant (P < 0.05 after Bonferroni correction for multiple testing) overrepresentation of the respective GO term (specified at the bottom).
Fig. 5Vulcano plot. Candidate proteins with significantly differential protein abundance (P < 0.05 after Benjamini-Hochberg correction for multiple testing) between paired vocal fold fibroblasts (VFF) and oral mucosa fibroblasts (OMF) are shown in red and specified by gene symbol.
Gene sets significantly enriched in vocal fold fibroblasts versus oral mucosa fibroblasts.
| Gene sets database | Gene sets significantly enriched in VFF versus OMF | FDR q-value | Gene symbols of proteins within core enrichment |
|---|---|---|---|
| Canonical pathways | NABA_MATRISOME | 0.0633 | P4HA1, PLOD2, FGF2, COL1A2, P4HA2, S100A2, COL6A1, SERPINH1, P3H1, ANXA3, COL12A1, PCOLCE, COL15A1, COL6A2 |
| NABA_MATRISOME_ASSOCIATED | 0.0689 | P4HA1, PLOD2, FGF2, P4HA2, S100A2, SERPINH1, P3H1, ANXA | |
| KEGG | KEGG_REGULATION_OF_ACTIN_CYTOSKELETON | 0.0440 | MYH10, FGF2, ACTN1, ITGA6, MYH9, PPP1R12A, VCL, ACTN4, ARPC3, RDX, ROCK1, CRK, IQGAP1, ROCK2, ACTB, ARPC4 |
| KEGG_FOCAL_ADHESION | 0.0507 | COL1A2, ACTN1, ITGA6, COL6A1, PPP1R12A, VCL, FLNB, ACTN4, PARVA, COL6A2, ROCK1, FLNA, CRK, COL6A3, TLN1, ROCK2, ACTB | |
| KEGG_TIGHT_JUNCTION | 0.0657 | MYH10, ACTN1, TJP1, EPB41L2, PPP2CB, MYH9, ACTN4 | |
| Reactome | – | – | – |
| Hallmark | HALLMARK_APICAL_JUNCTION | 0.0076 | MYH10, NEXN, ACTN1, TJP1, EPB41L2, MYH9, ACTA1, CNN2, VCL, ACTN4, PARVA |
| HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | 0.0084 | PLOD2, FGF2, COL1A2, TPM1, FERMT2, SERPINH1, TAGLN, DPYSL3, CALU, COL12A1, PCOLCE, COL6A2, FLNA, GJA1 | |
| Transcription factor targets | – | – | – |
| miRNA binding | TGTTTAC,MIR-30A-5P,MIR-30C,MIR-30D,MIR-30B,MIR-30E-5P | 0.0806 | PTGFRN, MYH10, VAT1, P4HA2, DOCK7, ITGA6, SEC23A, PPP1R12A, HSPA5, CALU, LPP, GFPT2, LIN7C, VAT1L, GJA1 |
| GO biological process | – | – | – |
| GO cellular component | – | – | – |
| GO molecular function | – | – | – |
Distinct gene set databases (column 1) were queried to identify gene sets (column 2) which are significantly (false discovery rate (FDR) q-value <0.1, column 3) VFF-enriched when comparing the protein expression profiles of VFF with OMF. Proteins (specified by gene symbol) detected in the VFF/OMF samples and having the strongest contribution to the enrichment result (“core enrichment”, as defined by the Gene Set Enrichment Analysis (GSEA) method) are listed in column 4.
Gene sets significantly enriched in oral mucosa fibroblasts versus vocal fold fibroblasts.
| Gene sets database | Gene sets significantly (FDR q-value <0.1) enriched in OMF versus VFF | FDR q-value | Gene symbols of proteins within core enrichment |
|---|---|---|---|
| Canonical pathways | – | – | – |
| KEGG | KEGG_SPLICEOSOME | 0.02613 | DDX39B, PUF60, DDX5, PRPF19, SRSF6, HNRNPU, HNRNPM, SRSF1, SNRNP70, HNRNPK, HNRNPC, SF3B1, PCBP1, SF3B2 |
| Reactome | REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA | 0.01592 | DHX9, SRSF6, HNRNPU, HNRNPM, HNRNPL, SRSF1, SNRNP70, HNRNPK, HNRNPC, SF3B1, PCBP1, TPR, SF3B2, PTBP1 |
| REACTOME_MRNA_SPLICING | 0.03449 | DHX9, SRSF6, HNRNPU, HNRNPM, HNRNPL, SRSF1, SNRNP70, HNRNPK, HNRNPC, SF3B1, PCBP1, SF3B2, PTBP1 | |
| REACTOME_MRNA_PROCESSING | 0.01884 | DHX9, SRSF6, HNRNPU, HNRNPM, HNRNPL, SRSF1, SNRNP70, HNRNPK, HNRNPC, SF3B1, PCBP1, TPR, SF3B2, PTBP1 | |
| REACTOME_METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS | 0.08798 | ACLY, HMGCS1, ME1, DHCR7, LBR | |
| Hallmark | HALLMARK_E2F_TARGETS | <10-E4 | CSE1L, PA2G4, SYNCRIP, RANBP1, SRSF1, PCNA, STMN1, PAICS, RBBP7, SMC3, MCM3, LMNB1, MCM6, H2AFX, RPA1, LBR |
| HALLMARK_G2M_CHECKPOINT | <10-E4 | SFPQ, HNRNPU, NCL, SYNCRIP, SRSF1, BUB3, STMN1, NUMA1, G3BP1, SMC2, MCM3, LMNB1, MCM6, H2AFX, LBR | |
| HALLMARK_MYC_TARGETS_V1 | 0.05351 | HSP90AB1, CCT4, PSMC6, YWHAE, RRM1, CCT7, PSMA4, CCT3, RAN, RPS5, KPNB1, PABPC4, FAM120A, RUVBL2, IMPDH2, DUT, PSMD3, HNRNPU, CCT5, TARDBP, PA2G4, PSMA1, SYNCRIP, RANBP1, SRSF1, SERBP1, PCNA, HNRNPC, BUB3, CBX3, CNBP, PCBP1, G3BP1, MCM6 | |
| Transcription factor targets | V$E2F1_Q4_01 | 0.00835 | KPNB1, RPS19, HIST1H1D, IMPDH2, NCL, RANBP1, SRSF1, SERBP1, PCNA, STMN1, CNBP, SMC3, SMC2, MCM3, DDX17, PTMA, MCM6, UCHL1 |
| V$E2F_Q3_01 | 0.03749 | KPNB1, RPS19, HIST1H1D, NCL, RANBP1, SRSF1, SERBP1, PCNA, STMN1, RALY, SMC3, NUMA1, SMC2, MCM3, DDX17, PTMA, MCM6, UCHL1 | |
| V$E2F_Q4_01 | 0.03923 | KPNB1, RPS19, HIST1H1D, IMPDH2, NCL, RANBP1, SRSF1, SERBP1, PCNA, STMN1, CNBP, SMC3, SMC2, MCM3, DDX17, PTMA, MCM6, UCHL1 | |
| V$USF_01 | 0.07438 | SAE1, RANBP1, STMN1, NUDC, EIF4B, SMC3, PTMA, RPA1 | |
| miRNA binding | – | – | – |
| GO biological process | CELL_PROLIFERATION_GO_0008283 | 0.02559 | FSCN1, CSE1L, PA2G4, PCNA, BUB3, NUDC, RBBP7, KHDRBS1, CCDC88A, APPL1, PRDX1 |
| RNA_SPLICING | 0.03236 | SFPQ, SRSF6, KHSRP, SYNCRIP, SRSF1, SNRNP70, HNRNPC, NONO, IVNS1ABP, SF3B2, PTBP1 | |
| GO cellular component | NUCLEAR_PART | <10-E4 | HNRNPU, PSMA1, HNRNPM, HNRNPL, SNRNP70, HNRNPK, HNRNPC, RALY, IVNS1ABP, SF3B2, PTBP1 |
| RIBONUCLEOPROTEIN_COMPLEX | 0.00929 | HNRNPU, PSMA1, HNRNPM, HNRNPL, SNRNP70, HNRNPK, HNRNPC, RALY, IVNS1ABP, SF3B2, PTBP1 | |
| NUCLEUS | 0.01046 | DUT, DDX19B, HNRNPU, RPS3A, TARDBP, PARP1, THRAP3, IPO5, NCL, CSE1L, TNPO1, PA2G4, PSMA1, SYNCRIP, RANBP1, HNRNPM, HNRNPL, SNRNP70, HNRNPK, PTRF, HNRNPC, MATR3, NONO, CBX3, EHD4, TPR, RALY, SMC3, NUMA1, IVNS1ABP, G3BP1, SMC2, SF3B2, KHDRBS1, MCM3, DDX17, LMNB1, PTBP1, PTMA, H2AFX, RPA1, DHCR7, ACTL6A, APPL1, NUP160, LBR | |
| NUCLEAR_ENVELOPE | 0.01540 | DDX19B, PARP1, IPO5, MATR3, TPR, LMNB1, DHCR7, NUP160, LBR | |
| NUCLEAR_LUMEN | 0.01985 | SRP68, LYAR, RPS19, RUVBL2, PARP1, THRAP3, NCL, HNRNPL, HNRNPK, SMC3, IVNS1ABP, PTBP1, RPA1, ACTL6A, APPL1 | |
| GO molecular function | DNA_BINDING | 0.02572 | HNRNPU, TARDBP, PARP1, PA2G4, CNBP, PCBP1, KHDRBS1, MCM3, RPA1, LBR |
Distinct gene set databases (column 1) were queried to identify gene sets (column 2) which are significantly (false discovery rate (FDR) q-value <0.1, column 3) OMF-enriched when comparing the protein expression profiles of VFF with OMF. Proteins (specified by gene symbol) detected in the VFF/OMF samples and having the strongest contribution to the enrichment result (“core enrichment”, as defined by the Gene Set Enrichment Analysis (GSEA) method) are listed in column 4.